): The Cancer Chemotherapy Training Program (CCTP) at Memorial Sloan- Kettering Cancer Center (MSKCC) supports training of promising individuals for academic laboratory or clinical research careers in the treatment of neoplastic disease. All of the vast resources of MSKCC are available for this program. Forty-three accomplished, independent investigators provide the prerequisite mentoring to the candidate. This includes: curricula for cancer biology, research methodology and ethical conduct, training and supervision of research; and, grant and manuscript preparation. Available laboratory cancer research opportunities include molecular biology, genetics, cell biology, immunology, cellular biochemistry, and molecular pharmacology related to cancer. Clinical research training encompasses phase, I, II, and III trials of chemotherapy and immunologic agents, pharmacology and pharmacokinetics, correlative studies with molecular markers, and combined-modality trials with medical, surgical, and radiation components. The CCTP Director and Co-Directors are responsible for the daily oversight; programmatical support is provided by the Fellowship Steering Committee which aids in the review of trainee proposals and preceptor support. All trainees are post-doctoral, having completed 12-18 months of clinical subspecialty training prior to research supported by the CCTP. The program is highly competitive with only 9% of the applicants for the Medical Oncology/Hematology Fellowship Program accepted for training. Minority applications are actively sought. During the last grant period, 52 trainees were supported by the CCTP, 31 of whom have graduated. Accomplishments include: A) 77% of the graduates secured academic positions upon matriculation; B) 93% published manuscripts relating to the mentored research during or subsequent to the funding period totaling over 170 manuscripts and 220 abstracts; and C) 90% of the trainees presented research at national or inter- national meetings or symposia. The CCTP provides support in an early, critical stage of development of the trainees research careers. This competing renewal summarizes the commitment of the applicants and successful training of academic Medical Oncologists/ Hematologists.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
5T32CA009207-24
Application #
6172057
Study Section
Subcommittee G - Education (NCI)
Program Officer
Eckstein, David J
Project Start
1977-09-30
Project End
2002-06-30
Budget Start
2000-07-01
Budget End
2001-06-30
Support Year
24
Fiscal Year
2000
Total Cost
$532,604
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Sabari, J K; Leonardi, G C; Shu, C A et al. (2018) PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Ann Oncol 29:2085-2091
Offin, Michael; Rizvi, Hira; Tenet, Megan et al. (2018) Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers. Clin Cancer Res :
Sharma, Sai Kiran; Chow, Andrew; Monette, Sebastien et al. (2018) Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Res 78:1820-1832
Avanzi, Mauro P; Yeku, Oladapo; Li, Xinghuo et al. (2018) Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System. Cell Rep 23:2130-2141
Hyman, David M; Piha-Paul, Sarina A; Won, Helen et al. (2018) HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature 554:189-194
Rekhtman, Natasha; Pietanza, Catherine M; Sabari, Joshua et al. (2018) Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. Mod Pathol 31:111-121
Bielski, Craig M; Donoghue, Mark T A; Gadiya, Mayur et al. (2018) Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer. Cancer Cell 34:852-862.e4
Chang, Matthew T; Bhattarai, Tripti Shrestha; Schram, Alison M et al. (2018) Accelerating Discovery of Functional Mutant Alleles in Cancer. Cancer Discov 8:174-183
Dunbar, Andrew; Nazir, Abbas; Levine, Ross (2017) Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Curr Protoc Pharmacol 77:14.40.1-14.40.19
Vardhana, Santosha A; Sauter, Craig S; Matasar, Matthew J et al. (2017) Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol 176:591-599

Showing the most recent 10 out of 195 publications